[The safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) for treatment of metastatic renal cell carcinoma].
Togo Y, Shimatani K, Hanasaki T, Yo T, Nakanishi Y, Nagasawa S, Hashimoto T, Shiraishi Y, Taoka R, Suzuki T, Go S, Higuchi Y, Kanematsu A, Nojima M, Tsuchihashi K, Makino Y, Shimizu Y, Kanamaru S, Kono Y, Matsumoto K, Utsunomiya N, Ito N, Kawakita M, Yamamoto S.
Togo Y, et al. Among authors: shiraishi y.
Hinyokika Kiyo. 2014 May;60(5):209-14.
Hinyokika Kiyo. 2014.
PMID: 24894855
Free article.
Japanese.